COMMUNIQUÉS West-GlobeNewswire

Saudi Food and Drug Authority, AAMI Partner on Medtech Best Practices
10/09/2025
SFDA and AAMI Sign Memorandum of Understanding Arlington, Virginia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has signed a memorandum of understanding with [...]
KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025
10/09/2025
RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) led Saudi healthcare institutions in clinical trials, conducting 48% of all clinical trials [...]
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program
10/09/2025
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program with an IND submission expected next year This NIH grant award strongly confirms the scientific and [...]
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
10/09/2025
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent Biologics to [...]
Les données publiées dans The New England Journal of Medicine démontrent que l’association de RYBREVANT®▼ (amivantamab) et de LAZCLUZE®▼ (lazertinib) serait susceptible de redéfinir les perspectives de survie dans le traitement de première
10/09/2025
Ce schéma thérapeutique combiné sans chimiothérapie pourrait ouvrir une nouvelle ère dans le traitement de première intention, avec une survie globale médiane prévue supérieure à quatre ans, dépassant ainsi de plus d’un [...]
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
10/09/2025
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
10/09/2025
BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with [...]
Purespring Therapeutics to Participate in the 2025 BofA Healthcare Trailblazers Private Company Conference
10/09/2025
London – 10 September 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announced that members of its management team will participate in the [...]
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
10/09/2025
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF [...]
OrthoPediatrics Corp. Completes First Procedures with VerteGlide™ Spinal Growth Guidance System
10/09/2025
WARSAW, Ind., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
10/09/2025
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma [...]
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
10/09/2025
- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a [...]
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
10/09/2025
SAN MATEO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
10/09/2025
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of [...]
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
10/09/2025
BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, [...]
Pharming Group promoted to the Euronext AMX® index
10/09/2025
Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® ( [...]
Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2
10/09/2025
Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2 Approbation basée sur l’étude TN-10, qui démontre la [...]
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
10/09/2025
Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 [...]
Novo Nordisk to streamline operations and reinvest for growth
10/09/2025
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients Intention to reduce ~9,000 roles globally with the [...]

Pages